The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months

Pharmacoepidemiology and Drug Safety - Tập 16 Số 7 - Trang 726-735 - 2007
Björn Wettermark1,2,3, Niklas Hammar1,4,5, C. MichaelFored1,6, Andrejs Leimanis7, Petra Otterblad Olausson7, Ulf Bergman2, Ingemar Persson8,9, Anders Sundström10, B Westerholm10, Måns Rosén7
1Board member, Swedish Society for Pharmacoepidemiology.
2Division of Clinical Pharmacology, Karolinska University Hospital, Huddinge. WHO collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, and Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
3National Corporation of Pharmacies (Apoteket AB), Stockholm, Sweden
4Department of Epidemiology, AstraZeneca Research and Development, Mölndal, Sweden
5Department of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
6Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital, and Centre for Pharmacoepidemiology, Karolinska Institutet, Stockholm, Sweden
7Centre for Epidemiology, Swedish National Board of Health and Welfare, Stockholm, Sweden
8Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
9Medical Products Agency, Uppsala, Sweden
10Swedish Association of Senior Citizens, Stockholm, Sweden

Tóm tắt

AbstractPurposeTo describe the content and potentials of the new Swedish national register on prescribed and dispensed medicines.MethodsThe Swedish Prescribed Drug Register contains information about age, sex and unique identifier of the patient as well as the prescriber's profession and practice. Information regarding drug utilization and expenditures for prescribed drugs in the entire Swedish population was extracted from the first six months July–December 2005 and compared with total drug sales in the country including OTC and hospital use.ResultsThe total quantity of drugs sold in Sweden was 2666 million DDDs, corresponding to 1608 DDD/1000 inhabitants daily. The total expenditures were 1.6 billion Euro. The prescribed drugs, included in the register, accounted for 84% of the total utilization and 77% of the total expenditures. About half of all men and two‐thirds of all women in the country purchased drugs. The proportion increased by age. The most common drugs for chronic treatment were diuretics among women (8.8% of the population) and antithrombotic agents among men (7.6%). Psychotropic drugs, corticosteroids and analgesics were more common among women, while men used antithrombotic agents, antidiabetic drugs, lipid lowering agents and ACE inhibitors to a greater extent.ConclusionsThe new register provides valuable data on exposure to drugs and is useful to study patterns of drug utilization. The possibilities for record linkage to other health registers gives from an international perspective good opportunities to explore drug and disease associations and the risks, benefits, effectiveness and health economical effects of drug use. Copyright © 2006 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

Strom B, 2005, Pharmacoepidemiology

10.1016/0895-4356(92)90092-2

Bergström K, 1971, Psychiatry. V World Congress of Psychiatry, Mexico

10.1007/BF00561402

10.1016/0021-9681(87)90101-9

Bergman U, 2001, Pharmacoepidemiology—from description to quality assessment. A Swedish perspective, Norwegian Journal of Epidemiology, 11, 31

National Board of Health and Welfare, 2003, Monitoring public health and social conditions in Sweden 1992–2002

10.1016/0168-8510(94)90050-7

World Health Organization (WHO) Oslo.Guidelines for ATC classification and DDD assignment. WHO Collaborating Centre for Drug Statistics Methodology Oslo 2005.www.whocc.no

ApoteketAB.Svensk Läkemedelsstatistik (Swedish Drug statistics).2005. Sales of medicines in Sweden. Swedish National Corporation of Pharmacies.www.apoteket.se

Bergman U, 1984, Measurement of drug utilization in Sweden: methodological and clinical implications, Acta Medica Scandinavia, 105, 15, 10.1111/j.0954-6820.1984.tb08709.x

10.1034/j.1600-0404.2001.00197.x

10.1002/pds.624

Wettermark B, 2001, Har vi råd med en bra kolesterolsänkande behandling? Budgetunderlag för behovsbaserade statinkostnader i Stockholms län [Can we afford good cholesterol lowering therapy? Budgeting of statin costs versus medical needs in the county of Stockholm], Läkartidningen, 98, 5472

10.1002/pds.1154

Haaijer‐RuskampFM HovenJL MolPGM.A conceptual framework for constructing prescribing quality indicators: a proposal. DURQUIM: drug utilization quality indicator meeting. Mechelen Belgium WHO Europe.2004.

10.1136/heart.88.3.229

10.1001/jama.279.18.1458

10.1111/j.1365-2125.2005.02355.x

10.1046/j.1365-2125.2000.00192.x

10.1007/s002280050360

10.1016/S0301-2115(00)00388-2

10.1016/j.reprotox.2005.01.010

10.1002/pds.580

10.1375/1369052012155

10.1111/j.1365-2710.1992.tb01306.x

World Health Organization (WHO).Adherence to Long‐term therapies: evidence for action.2003.

10.1001/jama.287.3.337

SundströmA JanssonK WiholmBE.The CCNET Control‐Pool: a database of 2000 randomly selected community controls in Sweden. Abstract presented at the ‘8th Annual Meeting—European Society of Pharmacovigilance’ Verona September2000. Conference‐book edited by Giampaolo Velo and Roberto Leone (Elsevier).

10.1016/S0140-6736(04)16261-2

10.1002/pds.1082

Swedish Health Data Registers Act(1998:543).

International Society of Pharmacoepidemiology (ISPE).Guidelines for Good Practice in Data Privacy Medical Record Confidentiality and Research in the interest of Public Health.http://www.pharmacoepi.org/resources/privacy.cfm

10.1002/pds.627

10.1136/bmj.328.7451.1300

Klaukka T, 2001, The Finnish database on drug utilisation, Norwegian Journal of Epidemiology, 11, 19

Strøm H, 2004, Reseptbasert legemiddelregister: Et viktig verktøy for å oppnå detaljert legemiddelstatistikk, (Article in Norwegian) Norsk Epidemiologi, 14, 53

Gaist D, 1997, The Danish prescription registries, Dan Med Bull, 44, 445

Thông tin
Thông tin xuất bản

Pharmacoepidemiology and Drug Safety

Tập 16 Số 7

726-735

Thông tin tác giả